SANTHERA PHARMACEUTICALS HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.5 CHF | 0.00% |
|
+4.28% | -3.16% |
| Apr. 25 | Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 71.48 | 126 | 53.93 | 55.82 | 75.32 | 87.54 | 87.54 |
| Enterprise Value (EV) 1 | 49.5 | 94.65 | 112.7 | 55.82 | 75.32 | 87.54 | 87.54 |
| P/E ratio | -0.86 x | -6.55 x | -0.55 x | -0.82 x | -1.18 x | - | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.26 x | 1.67 x | 3.59 x | -35 x | 10.1 x | 10.6 x | 1.71 x |
| EV / Revenue | 2.26 x | 1.67 x | 3.59 x | -35 x | 10.1 x | 10.6 x | 1.71 x |
| EV / EBITDA | -1,499,103 x | -22,219,616 x | -1,173,946 x | -1,410,932 x | -1,788,232 x | - | - |
| EV / FCF | -1,632,835 x | 50,463,532 x | -1,238,515 x | -1,494,203 x | -2,527,662 x | - | - |
| FCF Yield | -0% | 0% | -0% | -0% | -0% | - | - |
| Price to Book | 1.67 x | 5.87 x | - | 34.2 x | -2.13 x | - | - |
| Nbr of stocks (in thousands) | 1,060 | 1,111 | 1,926 | 4,197 | 5,458 | 9,215 | 9,215 |
| Reference price 2 | 67.40 | 113.4 | 28.00 | 13.30 | 13.80 | 9.500 | 9.500 |
| Announcement Date | 4/29/19 | 3/24/20 | 4/29/21 | 6/10/22 | 4/27/23 | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.66 | 75.38 | 15.01 | -1.595 | 7.473 | 8.29 | 51.09 |
| EBITDA | -47.68 | -5.671 | -45.94 | -39.57 | -42.12 | - | - |
| EBIT 1 | -51.42 | -10.44 | -53.08 | -56.89 | -51.98 | -48.01 | -32.64 |
| Operating Margin | -162.43% | -13.85% | -353.65% | 3,566.65% | -695.52% | -579.11% | -63.89% |
| Earnings before Tax (EBT) | -53.86 | -18.39 | -67.46 | -54.72 | -69.69 | - | - |
| Net income | -54.19 | -18.97 | -67.66 | -55.53 | -70.15 | - | - |
| Net margin | -171.17% | -25.17% | -450.82% | 3,481.25% | -938.66% | - | - |
| EPS | -78.60 | -17.30 | -50.80 | -16.20 | -11.70 | - | - |
| Free Cash Flow | -43.77 | 2.497 | -43.54 | -37.36 | -29.8 | - | - |
| FCF margin | -138.28% | 3.31% | -290.14% | 2,342.38% | -398.73% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/29/19 | 3/24/20 | 4/29/21 | 6/10/22 | 4/27/23 | - | - |
1CHF in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|
| Net sales 1 | 2.05 | 2.4 | 5.7 | 10.3 | 13.7 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -12.57 | -13.49 | - | - | - |
| Operating Margin | -613.07% | -562.17% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | - | - | - | - | - |
1CHF in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | 58.8 | - | - | - | - |
| Net Cash position | 22 | 31.4 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -1.279 x | - | - | - | - |
| Free Cash Flow | -43.8 | 2.5 | -43.5 | -37.4 | -29.8 | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - |
| Book Value Per Share | 40.40 | 19.30 | - | 0.3900 | -6.490 | - | - |
| Cash Flow per Share | - | - | -32.70 | - | - | - | - |
| Capex | 1.35 | - | - | - | - | - | - |
| Capex / Sales | 4.26% | - | - | - | - | - | - |
| Announcement Date | 4/29/19 | 3/24/20 | 4/29/21 | 6/10/22 | 4/27/23 | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.5
CHF
Average target price
30
CHF
Spread / Average Target
+215.79%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.16% | 95.7M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- SANN Stock
- Financials Santhera Pharmaceuticals Holding AG
